Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma

The association between glutathione S-transferase pi (GSTpi) and other clinicopathological parameters, response to chemotherapy and clinical outcome were investigated in chemotherapy naive epithelial ovarian cancer patients. Paraffin-embedded material from 55 patients were used for immunohistochemical analysis. All patients had received six cycles of cisplatinum-based chemotherapy and 41 of them were revalued by laparotomy. Pre- and post-chemotherapy GSTpi staining were detected in the cancer tissues of 18/55 (32.7%) and 5/14 (35.7%) patients, respectively. GSTpi expression was not associated with other clinicopathologic parameters. Of 17 patients with postoperative measurable residual disease clinical response was observed in 4/7 of GSTpi positive and in 9/10 GSTpi negative patients (p = 0.25). Pathologic complete response (pCR) was achieved in 5/8 of GSTpi positive and 11/22 of GSTpi negative cases (p = 0.69). There was no significant difference in overall survival and progression-free survival (PFS) according to initial GSTpi status. However the PFS of the five patients (median 22 +/- 5.9 months) who had postchemotherapy positive GSTpi was significantly shorter than the nine patients (10.0 +/- 2.19 months) who had negative GSTpi (p = 0.006). This difference was not observed in overall survival. These results suggest that initial immunohistochemical staining of GSTpi does not aid in the prediction of pCR and clinical outcome in patients with epithelial ovarian cancer. Nonetheless investigation of GSTpi expression after chemotherapy needs further evaluation.

Glutathion-S transferase PI; Epithelial ovarian cancer

[1] Gottesman M.M., Pastan I.: "The multidrug transporter, a doubleedged sword". J. Biol. Chem., 1988, 263, 12163.

[2] Schimke R.T.: "Gene amplification in cultured animal cells". Cell, 1984, 37, 705.

[3] Pegg A.E., Byers T.L.: "Rep狙r of DNA containing 0-alkylguanine". Faseb. J., 1992, 6, 2302.

[4] Wolf C.R., Worening C.J., Black S.M., Hayes J.D.: "Glutathione Stransferases in resistance to chemotherapeutic agents". In: J.D. Hayes, C.B. Pickett and T.J. Mantle (eds.). Glutathione S-transferases and drug resistance. London, Taylor and Francis, 1990, 295.

[5] Arrick B.A., Nathan C.F.: "Glutathione metabolism as a determinant of therapeutic efficacy". Cancer Res., 1984, 44, 4424.

[6] Meijer C., Mulder N.H., de V ries E.G.E.: "The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin". Cancer Treat. Rev., 1990, 17, 389.

[7] O'Brien M.L., Tew K.D.: "Glutathione and related enzymes in multidrug resistance". Eur. J. Cancer, 1996, 32A(6), 967.

[8] Green J.A., Robertson L.J., Clark A.H.: "Glutathione S-transferase expression in benign and malignant ovarian tumors". Br. J. Cancer, 1993, 68, 235.

[9] van der Zee A.G.J., van Ommen B., Meijer C., Hollema H., van Bladeren P.J., de Vries E.G.: "Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumors, untreated malignant ovarian tumors and malignant ovarian tumors after platinum/cyclophosphamide chemotherapy". Br. J. Cancer, 1992, 66, 229.

[10] Cheng X., Kigawa J., Minagawa Y., Kanamori Y., Itamochi H., Okada M., Terakawa N.: "Glutathione S transferase－π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy". Cancer, 1997, 79, 521.

[11] van der Zee Ate G.J., Hollema H., Suurmeijer A.J.H., Krans M. et al.: "Value of P-glycoprotein, glutathione S-transferase pi, c-erb-2 and p 53 as prognostic factors in ovarian carcinomas". J. Clin. Oneal., 1995, 13, 70.

[12] Hamada S.I., Kamada M.; Furumoto H., Aono T.: "Expression of Glutathione S-transferase-7t in human ovarian cancer as an indicator of resistance to chemotherapy". Gynecol. Oneal., 1994, 52, 313.

[13] Silvestrini R., Daidone M.G., Veneroni S., Benini E.R., Scarfone G., Zanaboni F. et al.: "The clinical predictivity of biomarkers of Stage III-IV epithelial ovarian cancer in a prospective randomised treatment protocol". Cancer, 1998, 82, 159.

[14] Codegoni A.M., Broggini M., Pitelli M.R., Pantarotto M., Torri V., Mangioni C., C'Incalci M.: "Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer". Gynecol. Oneal., 1997, 65, 130.

[15] Serov S.F., Scully R.E., Sobin L.H.: "Histological typing of ovarian tumors". Geneva, Switzerland, World Health Organization 1973, 17.

[16] International Federation of Gynecology and Obstetrics: "Changes in definitions of clinical staging for cancer of the cervix and ovary". Am. J. Obstet. Gynecol., 1987, 156, 236.

[17] Murphy D., McGown A.T., Hall A., Cattan A., Fox B.W., Crowther D.: "Glutathione S transferase activity and isoenzyme distribution in ovarian tumor biopsies taken before or after cytotoxic chemotherapy". Br. J. Cancer, 1992, 66, 937.

[18] Mayr D., Pannekamp U., Baretton G.B., Gropp M., Meier W., Flens M.J. et al.: "lmmunohistochemical analysis of drug resistance-associated proteins in ovarian carcinoma". Pathol. Res. Pract., 2000, 196, 469.

[19] Satoh T., Nishida M., Tsunoda H., Kubo T.: "Expression of gluthatione-S transferase pi (GST1t) in human malignant ovarian tumors". Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 96, 202.

[20] Germain I., Tetu B., Brisson J., Mondor M., Cherian M.G.: "Markers of chemoresistance in ovarian carcinomas: An immunohistochemical study of 86 cases". Int. J. Gynecol. Pathol., 1996, 15, 45.